Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid TumorsBASELGA, José; CERVANTES, Andres; SWAISLAND, Alan et al.Clinical cancer research (Print). 2010, Vol 16, Num 19, pp 4876-4883, issn 1078-0432, 8 p.Article

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinibHORAK, Jiri; WHITE, Jeff; TWELVES, Chris et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1485-1495, issn 0344-5704, 11 p.Article

Effects of the Src Inhibitor Saracatinib (AZD0530) on Renal Function in Healthy SubjectsDALTON, R. Neil; CHETTY, Raj; STUART, Mary et al.Anticancer research. 2010, Vol 30, Num 7, pp 2935-2942, issn 0250-7005, 8 p.Article

Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and NeckSTEWART, J. Simon W; COHEN, Ezra E. W; VARELLA-GARCIA, Marileila et al.Journal of clinical oncology. 2009, Vol 27, Num 11, pp 1864-1871, issn 0732-183X, 8 p.Article

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I studyGROSS, Mitchell E; LEICHMAN, Lawrence; LOWE, Elizabeth S et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 1, pp 273-280, issn 0344-5704, 8 p.Article

Gefitinib-phenytoin interaction is not correlated with the 14C-erythromycin breath test in healthy male volunteersCHHUN, Stephanie; VERSTUYFT, Celine; RIZZO-PADOIN, Nathalie et al.British journal of clinical pharmacology. 2009, Vol 68, Num 2, pp 226-237, issn 0306-5251, 12 p.Article

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaREARDON, David A; QUINN, Jennifer A; PROVENZALE, James M et al.Clinical cancer research. 2006, Vol 12, Num 3, pp 860-868, issn 1078-0432, 9 p., 1Article